(BIO) Bio-Rad Laboratories - Ratings and Ratios
Instruments, Reagents, Test Systems, Consumables, Controls
BIO EPS (Earnings per Share)
BIO Revenue
Description: BIO Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. is a global leader in the life science research and clinical diagnostics industries, operating through two main segments: Life Science and Clinical Diagnostics. The companys products are used in various applications, including biopharmaceutical manufacturing, quality control, food safety, and science education. Its offerings include instruments, systems, reagents, and consumables for separating, purifying, characterizing, and quantifying biological materials.
From a business perspective, Bio-Rad Laboratories has a strong presence in the global market, with a diverse customer base across hospitals, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. The companys products are sold through a combination of direct sales forces and distribution networks, including distributors, agents, brokers, and resellers. With a history dating back to 1952, Bio-Rad Laboratories has established itself as a reputable player in the industry.
Evaluating the companys performance using key performance indicators (KPIs), we can consider metrics such as revenue growth, gross margin, and operating margin. Bio-Rad Laboratories revenue growth has been driven by its expanding product portfolio and global reach. The companys gross margin is likely influenced by its product mix, with a high proportion of consumables and reagents contributing to a relatively stable margin. Operating margin is also an important metric, as it reflects the companys ability to manage its operating expenses and maintain profitability.
From a financial perspective, Bio-Rad Laboratories has a market capitalization of approximately $6.85 billion, with a forward price-to-earnings ratio of 31.75. While the companys return on equity (ROE) is currently negative, this metric can be influenced by various factors, including accounting adjustments and one-time events. A more detailed analysis of the companys financial statements would be necessary to understand the underlying drivers of its ROE.
In terms of stock performance, Bio-Rad Laboratories shares have fluctuated in recent times, with a current price of $264.19. The stocks moving averages, including the 20-day, 50-day, and 200-day SMAs, provide insight into its short-term and long-term trends. Further analysis of the stocks technical indicators, such as relative strength index (RSI) and Bollinger Bands, could help identify potential trading opportunities.
BIO Stock Overview
| Market Cap in USD | 7,637m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 1966-01-01 |
BIO Stock Ratings
| Growth Rating | -66.4% |
| Fundamental | 52.9% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -28.2% |
| Analyst Rating | 4.0 of 5 |
BIO Dividends
Currently no dividends paidBIO Growth Ratios
| Growth Correlation 3m | 90.5% |
| Growth Correlation 12m | -66.1% |
| Growth Correlation 5y | -91% |
| CAGR 5y | -14.63% |
| CAGR/Max DD 3y | -0.26 |
| CAGR/Mean DD 3y | -0.43 |
| Sharpe Ratio 12m | 0.00 |
| Alpha | -29.98 |
| Beta | 0.717 |
| Volatility | 39.32% |
| Current Volume | 242.4k |
| Average Volume 20d | 199.1k |
| Stop Loss | 269 (-4%) |
| Signal | -0.98 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (319.2m TTM) > 0 and > 6% of Revenue (6% = 153.3m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA 1.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 88.57% (prev 100.3%; Δ -11.69pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 534.2m > Net Income 319.2m (YES >=105%, WARN >=100%) |
| Net Debt (1.04b) to EBITDA (686.2m) ratio: 1.51 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (27.2m) change vs 12m ago -4.11% (target <= -2.0% for YES) |
| Gross Margin 52.82% (prev 54.00%; Δ -1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 25.67% (prev 26.45%; Δ -0.78pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 10.19 (EBITDA TTM 686.2m / Interest Expense TTM 49.0m) >= 6 (WARN >= 3) |
Altman Z'' 6.88
| (A) 0.22 = (Total Current Assets 2.81b - Total Current Liabilities 548.9m) / Total Assets 10.21b |
| (B) 0.76 = Retained Earnings (Balance) 7.80b / Total Assets 10.21b |
| (C) 0.05 = EBIT TTM 499.1m / Avg Total Assets 9.95b |
| (D) 2.48 = Book Value of Equity 7.64b / Total Liabilities 3.09b |
| Total Rating: 6.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 52.90
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 4.08% = 2.04 |
| 3. FCF Margin 13.61% = 3.40 |
| 4. Debt/Equity 0.17 = 2.49 |
| 5. Debt/Ebitda 1.81 = 0.37 |
| 6. ROIC - WACC -2.87% = -3.58 |
| 7. RoE 4.58% = 0.38 |
| 8. Rev. Trend -62.46% = -3.12 |
| 9. Rev. CAGR -1.58% = -0.26 |
| 10. EPS Trend 7.47% = 0.19 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BIO shares?
Over the past week, the price has changed by -3.46%, over one month by -2.39%, over three months by +20.99% and over the past year by -15.12%.
Is Bio-Rad Laboratories a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BIO is around 243.85 USD . This means that BIO is currently overvalued and has a potential downside of -13.02%.
Is BIO a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BIO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 331.2 | 18.1% |
| Analysts Target Price | 331.2 | 18.1% |
| ValueRay Target Price | 269.6 | -3.8% |
Last update: 2025-09-12 04:32
BIO Fundamental Data Overview
CCE Cash And Equivalents = 369.3m USD (last quarter)
P/E Trailing = 25.8033
P/E Forward = 29.5858
P/S = 2.9899
P/B = 1.0854
P/EG = 1.1905
Beta = 0.956
Revenue TTM = 2.55b USD
EBIT TTM = 499.1m USD
EBITDA TTM = 686.2m USD
Long Term Debt = 1.20b USD (from longTermDebt, last quarter)
Short Term Debt = 40.6m USD (from shortTermDebt, last quarter)
Debt = 1.24b USD (Calculated: Short Term 40.6m + Long Term 1.20b)
Net Debt = 1.04b USD (from netDebt column, last quarter)
Enterprise Value = 8.51b USD (7.64b + Debt 1.24b - CCE 369.3m)
Interest Coverage Ratio = 10.19 (Ebit TTM 499.1m / Interest Expense TTM 49.0m)
FCF Yield = 4.08% (FCF TTM 347.5m / Enterprise Value 8.51b)
FCF Margin = 13.61% (FCF TTM 347.5m / Revenue TTM 2.55b)
Net Margin = 12.50% (Net Income TTM 319.2m / Revenue TTM 2.55b)
Gross Margin = 52.82% ((Revenue TTM 2.55b - Cost of Revenue TTM 1.20b) / Revenue TTM)
Tobins Q-Ratio = 1.11 (Enterprise Value 8.51b / Book Value Of Equity 7.64b)
Interest Expense / Debt = 1.01% (Interest Expense 12.6m / Debt 1.24b)
Taxrate = 23.24% (96.2m / 414.0m)
NOPAT = 383.1m (EBIT 499.1m * (1 - 23.24%))
Current Ratio = 5.12 (Total Current Assets 2.81b / Total Current Liabilities 548.9m)
Debt / Equity = 0.17 (Debt 1.24b / last Quarter total Stockholder Equity 7.13b)
Debt / EBITDA = 1.81 (Net Debt 1.04b / EBITDA 686.2m)
Debt / FCF = 3.57 (Debt 1.24b / FCF TTM 347.5m)
Total Stockholder Equity = 6.97b (last 4 quarters mean)
RoA = 3.12% (Net Income 319.2m, Total Assets 10.21b )
RoE = 4.58% (Net Income TTM 319.2m / Total Stockholder Equity 6.97b)
RoCE = 6.11% (Ebit 499.1m / (Equity 6.97b + L.T.Debt 1.20b))
RoIC = 4.69% (NOPAT 383.1m / Invested Capital 8.17b)
WACC = 7.56% (E(7.64b)/V(8.88b) * Re(8.66%)) + (D(1.24b)/V(8.88b) * Rd(1.01%) * (1-Tc(0.23)))
Shares Correlation 3-Years: -90.91 | Cagr: -0.80%
Discount Rate = 8.66% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 78.79% ; FCFE base≈279.5m ; Y1≈329.5m ; Y5≈506.2m
Fair Price DCF = 351.0 (DCF Value 7.72b / Shares Outstanding 22.0m; 5y FCF grow 19.05% → 3.0% )
Revenue Correlation: -62.46 | Revenue CAGR: -1.58%
Rev Growth-of-Growth: 5.41
EPS Correlation: 7.47 | EPS CAGR: 0.0%
EPS Growth-of-Growth: -53.74
Additional Sources for BIO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle